<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01991470</url>
  </required_header>
  <id_info>
    <org_study_id>CEP249</org_study_id>
    <nct_id>NCT01991470</nct_id>
  </id_info>
  <brief_title>CEP249 Pediatric Accuracy Study</brief_title>
  <official_title>A Performance Evaluation of the Enlite™ and Enlite 3 Glucose Sensor to Support Use in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Diabetes</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Diabetes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the Enlite Sensor™ and Enlite 3 Sensor performance
      in pediatric patients with insulin requiring diabetes at the beginning, middle and end of
      sensor wear.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, single arm, multi-center, in-clinic study.. There will be two
      consecutive phases of the study:

      A total of up to 260 subjects (2-18 years old) will be enrolled at up to 15 investigational
      centers

      Subjects will come for clinic visit for YSI reference glucose testing and for Enlite Sensor™
      and Enlite 3 Sensor™ testing. SMBG (Self-Monitoring of Blood Glucose) reference measurement
      is for subjects 2-6 years of age and cannot tolerate YSI.

      Study has a run-in period and a study period with a total of 10 visits
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Enlite Sensor Accuracy Mean Absolute Relative Difference (MARD), With Lower Serial Number 530G Pump</measure>
    <time_frame>6 days</time_frame>
    <description>Enlite Sensor accuracy relative to the YSI (Yellow Spring Instruments) reference. Each subject wore two 530G pumps. The results for the lower serial number pump worn by each subject were arbitrarily selected and pooled across subjects for the primary dataset. MARD = Mean of ((Absolute difference of YSI reference and Sensor glucose values / YSI reference glucose values) * 100). Therefore, the unit of MARD is percentage (%). Note that results from multiple testing days were pooled together for reporting purpose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Enlite 3 Sensor Accuracy Mean Absolute Relative Difference (MARD), With the Guardian Mobile System</measure>
    <time_frame>7 days</time_frame>
    <description>Enlite 3 Sensor accuracy using Guardian Mobile System compared to YSI or SMBG (Self-Monitoring of Blood Glucose) reference values. For subjects 2-6 years of age, SMBG was used as a reference value if YSI cannot be tolerated. MARD = Mean of ((Absolute difference of reference and Sensor glucose values / reference glucose values) * 100). Therefore, the unit of MARD is percentage (%). Note that results from multiple testing days will be pooled together for reporting purpose.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Enlite 3 Sensor Accuracy Mean Absolute Relative Difference (MARD), With the GST3C Transmitter</measure>
    <time_frame>7 days</time_frame>
    <description>Enlite 3 Sensor accuracy using GST3C transmitter used as a recorder compared to YSI or SMBG reference values. For subjects 2-6 years of age, SMBG was used as a reference value if YSI cannot be tolerated. MARD = Mean of ((Absolute difference of reference and Sensor glucose values / reference glucose values) * 100). Therefore, the unit of MARD is percentage (%). Note that results from multiple testing days will be pooled together for reporting purpose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Enlite Sensor Accuracy Mean Absolute Relative Difference (MARD), With Higher Serial Number 530G Pump</measure>
    <time_frame>6 Days</time_frame>
    <description>Enlite Sensor accuracy relative to the YSI reference. Each subject wore two 530G pumps. The results for the higher serial number pump worn by each subject were arbitrarily selected and pooled across subjects for the secondary dataset. MARD = Mean of ((Absolute difference of YSI reference and Sensor glucose values / YSI reference glucose values) * 100). Therefore, the unit of MARD is percentage (%). Note that results from multiple testing days were pooled together for reporting purpose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Enlite Sensor Accuracy Mean Absolute Relative Difference (MARD), With Lower Serial Number 530G Pump, Using One Additional Calibration During FST</measure>
    <time_frame>6 Days</time_frame>
    <description>Enlite Sensor accuracy relative to the YSI reference, using one additional calibration during FST. MARD = Mean of ((Absolute difference of YSI reference and Sensor glucose values / YSI reference glucose values) * 100). Therefore, the unit of MARD is percentage (%). Note that results from multiple testing days were pooled together for reporting purpose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Enlite Sensor Accuracy Mean Absolute Relative Difference (MARD), With Higher Serial Number 530G Pump, Using One Additional Calibration During FST</measure>
    <time_frame>6 Days</time_frame>
    <description>Enlite Sensor accuracy relative to the YSI reference, using one additional calibration during FST. MARD = Mean of ((Absolute difference of YSI reference and Sensor glucose values / YSI reference glucose values) * 100). Therefore, the unit of MARD is percentage (%). Note that results from multiple testing days were pooled together for reporting purpose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Enlite 3 Sensor Accuracy Mean Absolute Relative Difference (MARD), With the Guardian Mobile System, Using One Additional Calibration During FST</measure>
    <time_frame>7 Days</time_frame>
    <description>Enlite 3 Sensor accuracy using Guardian Mobile System compared to YSI or SMBG reference values, with one additional calibration during FST. For subjects 2-6 years of age, SMBG was used as a reference value if YSI cannot be tolerated. MARD = Mean of ((Absolute difference of reference and Sensor glucose values / reference glucose values) * 100). Therefore, the unit of MARD is percentage (%). Note that results from multiple testing days will be pooled together for reporting purpose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Enlite 3 Sensor Accuracy Mean Absolute Relative Difference (MARD), With GST3C Transmitter, Using One Additional Calibration During FST</measure>
    <time_frame>7 Days</time_frame>
    <description>Enlite 3 Sensor accuracy using GST3C transmitter used as a recorder compared to YSI or SMBG reference values, with one additional calibration during FST. For subjects 2-6 years of age, SMBG was used as a reference value if YSI cannot be tolerated. MARD = Mean of ((Absolute difference of reference and Sensor glucose values / reference glucose values) * 100). Therefore, the unit of MARD is percentage (%). Note that results from multiple testing days will be pooled together for reporting purpose.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">186</enrollment>
  <condition>Insulin Requiring Diabetes</condition>
  <arm_group>
    <arm_group_label>Enlite sensors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will first wear enlite sensors and will come for clinic visit for YSI (Yellow Spring Instruments). Then each subject will wear enlite 3 sensors and will come for clinic visit for YSI (Yellow Spring Instruments) or SMBG (Self-Monitoring of Blood Glucose) testing. SMBG testings are for subjects 2-6 years of age and cannot tolerate YSI. In addition. In addition, subjects aged 2-6 years old will not participate in Enlite phase. They only participate in Enlite 3 phase.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Enlite sensors</intervention_name>
    <description>Subject wears enlite sensor first and followed by enlite 3 sensor.</description>
    <arm_group_label>Enlite sensors</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is 2-18 years of age at time of screening

          2. Subject has been diagnosed with insulin requiring diabetes mellitus for at least one
             year.

          3. Subject is willing to perform greater than or equal to 4 finger stick blood glucose
             measurements daily

          4. Subject is willing to perform required sensor calibrations

          5. Subject is willing to wear the system (Guardian Mobile application, pumps, sensors,
             meter) continuously throughout the study

          6. Adequate venous access as assessed by investigator or appropriate staff

        Exclusion Criteria:

          1. Subject is unable to tolerate tape adhesive in the area of sensor placement

          2. Subject has any unresolved adverse skin condition in the area of sensor or device
             placement (e.g., psoriasis, rash, Staphylococcus infection)

          3. Subject is actively participating in an investigational study (drug or device) wherein
             they have received treatment from an investigational study (drug or device) in the
             last 2 weeks

          4. Females of child-bearing potential who have a positive pregnancy test at screening or
             plans to become pregnant during the course of the study

          5. Subjects with hematocrit lower than the normal age specific reference range per
             central or local lab testing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald Brazg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rainier Clinical Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Timothy Bailey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AMCR Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeanie Tryggestad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>OUHSC Department of Pediatrics</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Linda DiMeglio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University, Riley Hospital for Children</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Larry Fox, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nemours Children's Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jennifer Sherr, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University, Yale Diabetes Research Program</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Slover, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barbara Davis Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eva Tsalikian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa Children Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bruce Bode, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Atlanta Diabetes Associates</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kevin Kaiserman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SoCal Diabetes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Christiansen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Diablo Clinical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AMCR Institute</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SoCal Diabetes</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diablo Clinical Research</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barbara Davis Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University, Yale Diabetes Research Program</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Atlanta Diabetes Associates</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University, Riley Hospital for Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Children Hospital</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OUHSC Department of Pediatrics</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rainier Clinical Research Center</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>November 18, 2013</study_first_submitted>
  <study_first_submitted_qc>November 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2013</study_first_posted>
  <results_first_submitted>December 19, 2017</results_first_submitted>
  <results_first_submitted_qc>August 28, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">September 27, 2018</results_first_posted>
  <last_update_submitted>August 28, 2018</last_update_submitted>
  <last_update_submitted_qc>August 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Insulin requiring diabetes</keyword>
  <keyword>Children</keyword>
  <keyword>Sensor</keyword>
  <keyword>Accuracy</keyword>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Two phase study: Enlite and Enlite 3. Some participated only Enlite phase and some only participated in Enlite 3 phase.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>2-18 Years Old Wearing Sensors</title>
          <description>2-18 years old wearing Enlite and/or Enlite3 sensors.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Enlite 1 Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="161"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="141"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inclusion/Exclusion not met</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Enlite 3 Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="158">Additional 25 subjects who participated only Enlite 3 phase</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="146"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>DUE TO MULTIPLE SENSOR ISSUES</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>a total of 186 subjects participated the study</population>
      <group_list>
        <group group_id="B1">
          <title>2-18 Year Olds Wearing Enlite Sensor</title>
          <description>2-18 years old wearing Enlite and/or Enlite3 sensors.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="186"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.2" spread="3.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Enlite Sensor Accuracy Mean Absolute Relative Difference (MARD), With Lower Serial Number 530G Pump</title>
        <description>Enlite Sensor accuracy relative to the YSI (Yellow Spring Instruments) reference. Each subject wore two 530G pumps. The results for the lower serial number pump worn by each subject were arbitrarily selected and pooled across subjects for the primary dataset. MARD = Mean of ((Absolute difference of YSI reference and Sensor glucose values / YSI reference glucose values) * 100). Therefore, the unit of MARD is percentage (%). Note that results from multiple testing days were pooled together for reporting purpose.</description>
        <time_frame>6 days</time_frame>
        <population>All subjects wearing Enlite sensor with lower serial number of 530G pump. A total of 30 subjects did not have device data.</population>
        <group_list>
          <group group_id="O1">
            <title>Enlite Sensor Accuracy MARD, Lower Serial Number</title>
            <description>Enlite Sensor accuracy relative to the YSI reference. Each subject wore two 530G pumps. The results for the lower serial number pump worn by each subject were arbitrarily selected and pooled across subjects for the primary dataset. MARD = Mean of ((Absolute difference of YSI reference and Sensor glucose values / YSI reference glucose values) * 100). Note that results from multiple testing days were pooled together for reporting purpose.</description>
          </group>
        </group_list>
        <measure>
          <title>Enlite Sensor Accuracy Mean Absolute Relative Difference (MARD), With Lower Serial Number 530G Pump</title>
          <description>Enlite Sensor accuracy relative to the YSI (Yellow Spring Instruments) reference. Each subject wore two 530G pumps. The results for the lower serial number pump worn by each subject were arbitrarily selected and pooled across subjects for the primary dataset. MARD = Mean of ((Absolute difference of YSI reference and Sensor glucose values / YSI reference glucose values) * 100). Therefore, the unit of MARD is percentage (%). Note that results from multiple testing days were pooled together for reporting purpose.</description>
          <population>All subjects wearing Enlite sensor with lower serial number of 530G pump. A total of 30 subjects did not have device data.</population>
          <units>percentage of difference</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.02" spread="13.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Enlite 3 Sensor Accuracy Mean Absolute Relative Difference (MARD), With the Guardian Mobile System</title>
        <description>Enlite 3 Sensor accuracy using Guardian Mobile System compared to YSI or SMBG (Self-Monitoring of Blood Glucose) reference values. For subjects 2-6 years of age, SMBG was used as a reference value if YSI cannot be tolerated. MARD = Mean of ((Absolute difference of reference and Sensor glucose values / reference glucose values) * 100). Therefore, the unit of MARD is percentage (%). Note that results from multiple testing days will be pooled together for reporting purpose.</description>
        <time_frame>7 days</time_frame>
        <population>a total of 25 subjects do not have device data</population>
        <group_list>
          <group group_id="O1">
            <title>Enlite 3 Sensor Accuracy MARD, Guardian Mobile</title>
            <description>Enlite 3 Sensor accuracy using Guardian Mobile System compared to YSI or SMBG reference values. For subjects 2-6 years of age, SMBG was used as a reference value if YSI cannot be tolerated. MARD = Mean of ((Absolute difference of reference and Sensor glucose values / reference glucose values) * 100). Therefore, the unit of MARD is percentage (%). Note that results from multiple testing days will be pooled together for reporting purpose.</description>
          </group>
        </group_list>
        <measure>
          <title>Enlite 3 Sensor Accuracy Mean Absolute Relative Difference (MARD), With the Guardian Mobile System</title>
          <description>Enlite 3 Sensor accuracy using Guardian Mobile System compared to YSI or SMBG (Self-Monitoring of Blood Glucose) reference values. For subjects 2-6 years of age, SMBG was used as a reference value if YSI cannot be tolerated. MARD = Mean of ((Absolute difference of reference and Sensor glucose values / reference glucose values) * 100). Therefore, the unit of MARD is percentage (%). Note that results from multiple testing days will be pooled together for reporting purpose.</description>
          <population>a total of 25 subjects do not have device data</population>
          <units>percentage of difference</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.88" spread="10.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Enlite 3 Sensor Accuracy Mean Absolute Relative Difference (MARD), With the GST3C Transmitter</title>
        <description>Enlite 3 Sensor accuracy using GST3C transmitter used as a recorder compared to YSI or SMBG reference values. For subjects 2-6 years of age, SMBG was used as a reference value if YSI cannot be tolerated. MARD = Mean of ((Absolute difference of reference and Sensor glucose values / reference glucose values) * 100). Therefore, the unit of MARD is percentage (%). Note that results from multiple testing days will be pooled together for reporting purpose.</description>
        <time_frame>7 days</time_frame>
        <population>A total of 41 subjects did not have device data.</population>
        <group_list>
          <group group_id="O1">
            <title>Enlite 3 Sensor Accuracy MARD,GST 3C</title>
            <description>Enlite 3 Sensor accuracy using GST3C transmitter used as a recorder compared to YSI or SMBG reference values. For subjects 2-6 years of age, SMBG was used as a reference value if YSI cannot be tolerated. MARD = Mean of ((Absolute difference of reference and Sensor glucose values / reference glucose values) * 100). Therefore, the unit of MARD is percentage (%). Note that results from multiple testing days will be pooled together for reporting purpose.</description>
          </group>
        </group_list>
        <measure>
          <title>Enlite 3 Sensor Accuracy Mean Absolute Relative Difference (MARD), With the GST3C Transmitter</title>
          <description>Enlite 3 Sensor accuracy using GST3C transmitter used as a recorder compared to YSI or SMBG reference values. For subjects 2-6 years of age, SMBG was used as a reference value if YSI cannot be tolerated. MARD = Mean of ((Absolute difference of reference and Sensor glucose values / reference glucose values) * 100). Therefore, the unit of MARD is percentage (%). Note that results from multiple testing days will be pooled together for reporting purpose.</description>
          <population>A total of 41 subjects did not have device data.</population>
          <units>percentage of difference</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.08" spread="10.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Enlite Sensor Accuracy Mean Absolute Relative Difference (MARD), With Higher Serial Number 530G Pump</title>
        <description>Enlite Sensor accuracy relative to the YSI reference. Each subject wore two 530G pumps. The results for the higher serial number pump worn by each subject were arbitrarily selected and pooled across subjects for the secondary dataset. MARD = Mean of ((Absolute difference of YSI reference and Sensor glucose values / YSI reference glucose values) * 100). Therefore, the unit of MARD is percentage (%). Note that results from multiple testing days were pooled together for reporting purpose.</description>
        <time_frame>6 Days</time_frame>
        <population>All subjects wearing Enlite sensors with high serial number 530G pump. A total of 35 subjects did not have device data.</population>
        <group_list>
          <group group_id="O1">
            <title>Enlite Sensor Accuracy MARD, Higher Serial Number</title>
            <description>Enlite Sensor accuracy relative to the YSI reference. Each subject wore two 530G pumps. The results for the higher serial number pump worn by each subject were arbitrarily selected and pooled across subjects for the secondary dataset. MARD = Mean of ((Absolute difference of YSI reference and Sensor glucose values / YSI reference glucose values) * 100). Therefore, the unit of MARD is percentage (%). Note that results from multiple testing days were pooled together for reporting purpose.</description>
          </group>
        </group_list>
        <measure>
          <title>Enlite Sensor Accuracy Mean Absolute Relative Difference (MARD), With Higher Serial Number 530G Pump</title>
          <description>Enlite Sensor accuracy relative to the YSI reference. Each subject wore two 530G pumps. The results for the higher serial number pump worn by each subject were arbitrarily selected and pooled across subjects for the secondary dataset. MARD = Mean of ((Absolute difference of YSI reference and Sensor glucose values / YSI reference glucose values) * 100). Therefore, the unit of MARD is percentage (%). Note that results from multiple testing days were pooled together for reporting purpose.</description>
          <population>All subjects wearing Enlite sensors with high serial number 530G pump. A total of 35 subjects did not have device data.</population>
          <units>percentage of difference</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.50" spread="19.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Enlite Sensor Accuracy Mean Absolute Relative Difference (MARD), With Lower Serial Number 530G Pump, Using One Additional Calibration During FST</title>
        <description>Enlite Sensor accuracy relative to the YSI reference, using one additional calibration during FST. MARD = Mean of ((Absolute difference of YSI reference and Sensor glucose values / YSI reference glucose values) * 100). Therefore, the unit of MARD is percentage (%). Note that results from multiple testing days were pooled together for reporting purpose.</description>
        <time_frame>6 Days</time_frame>
        <population>A total of 32 subjects did not have device data.</population>
        <group_list>
          <group group_id="O1">
            <title>Enlite Sensor Accuracy MARD, Lower Serial Number</title>
            <description>Enlite Sensor accuracy using two 530G pumps and two REAL-Time transmitters with one additional calibration during FST will be evaluated and report separately (e.g., lower serial number and high serial number)Enlite sensor values will be compared to Yellow Spring Instruments (YSI) plasma glucose values during Frequent Sample Testing in the Enlite phase. MARD = Mean of ((Absolute difference of YSI reference and Sensor glucose values / YSI reference glucose values) * 100). Note that results from multiple testing days will be pooled together for reporting purpose.</description>
          </group>
        </group_list>
        <measure>
          <title>Enlite Sensor Accuracy Mean Absolute Relative Difference (MARD), With Lower Serial Number 530G Pump, Using One Additional Calibration During FST</title>
          <description>Enlite Sensor accuracy relative to the YSI reference, using one additional calibration during FST. MARD = Mean of ((Absolute difference of YSI reference and Sensor glucose values / YSI reference glucose values) * 100). Therefore, the unit of MARD is percentage (%). Note that results from multiple testing days were pooled together for reporting purpose.</description>
          <population>A total of 32 subjects did not have device data.</population>
          <units>percentage of difference</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.37" spread="12.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Enlite Sensor Accuracy Mean Absolute Relative Difference (MARD), With Higher Serial Number 530G Pump, Using One Additional Calibration During FST</title>
        <description>Enlite Sensor accuracy relative to the YSI reference, using one additional calibration during FST. MARD = Mean of ((Absolute difference of YSI reference and Sensor glucose values / YSI reference glucose values) * 100). Therefore, the unit of MARD is percentage (%). Note that results from multiple testing days were pooled together for reporting purpose.</description>
        <time_frame>6 Days</time_frame>
        <population>A total of 34 subjects did not have device data.</population>
        <group_list>
          <group group_id="O1">
            <title>Enlite Sensor Accuracy MARD, Higher Serial Number</title>
            <description>Enlite Sensor accuracy using two 530G pumps and two REAL-Time transmitters with one additional calibration during FST will be evaluated and report separately (e.g., lower serial number and high serial number) Enlite sensor values will be compared to Yellow Spring Instruments (YSI) plasma glucose values during Frequent Sample Testing in the Enlite phase. MARD = Mean of ((Absolute difference of YSI reference and Sensor glucose values / YSI reference glucose values) * 100). Note that results from multiple testing days will be pooled together for reporting purpose.</description>
          </group>
        </group_list>
        <measure>
          <title>Enlite Sensor Accuracy Mean Absolute Relative Difference (MARD), With Higher Serial Number 530G Pump, Using One Additional Calibration During FST</title>
          <description>Enlite Sensor accuracy relative to the YSI reference, using one additional calibration during FST. MARD = Mean of ((Absolute difference of YSI reference and Sensor glucose values / YSI reference glucose values) * 100). Therefore, the unit of MARD is percentage (%). Note that results from multiple testing days were pooled together for reporting purpose.</description>
          <population>A total of 34 subjects did not have device data.</population>
          <units>percentage of difference</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.94" spread="18.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Enlite 3 Sensor Accuracy Mean Absolute Relative Difference (MARD), With the Guardian Mobile System, Using One Additional Calibration During FST</title>
        <description>Enlite 3 Sensor accuracy using Guardian Mobile System compared to YSI or SMBG reference values, with one additional calibration during FST. For subjects 2-6 years of age, SMBG was used as a reference value if YSI cannot be tolerated. MARD = Mean of ((Absolute difference of reference and Sensor glucose values / reference glucose values) * 100). Therefore, the unit of MARD is percentage (%). Note that results from multiple testing days will be pooled together for reporting purpose.</description>
        <time_frame>7 Days</time_frame>
        <population>A total of 34 subjects did not have device data.</population>
        <group_list>
          <group group_id="O1">
            <title>Enlite 3 MARD, Guardian Mobile, One Additional Fingerstick</title>
            <description>Enlite 3 Sensor accuracy using, (1) Guardian Mobile System (2) GST 3C transmitter, with one additional calibration during FST will be evaluated and report. Enlite 3 sensor values will be compared to Yellow Spring Instruments (YSI) plasma glucose values during Frequent Sample Testing in the Enlite 3 phase. For subjects 2-6 years of age, SMBG may be used as a reference value. MARD = Mean of ((Absolute difference of reference and Sensor glucose values / reference glucose values) * 100). Note that results from multiple testing days will be pooled together for reporting purpose.</description>
          </group>
        </group_list>
        <measure>
          <title>Enlite 3 Sensor Accuracy Mean Absolute Relative Difference (MARD), With the Guardian Mobile System, Using One Additional Calibration During FST</title>
          <description>Enlite 3 Sensor accuracy using Guardian Mobile System compared to YSI or SMBG reference values, with one additional calibration during FST. For subjects 2-6 years of age, SMBG was used as a reference value if YSI cannot be tolerated. MARD = Mean of ((Absolute difference of reference and Sensor glucose values / reference glucose values) * 100). Therefore, the unit of MARD is percentage (%). Note that results from multiple testing days will be pooled together for reporting purpose.</description>
          <population>A total of 34 subjects did not have device data.</population>
          <units>percentage of difference</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.05" spread="9.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Enlite 3 Sensor Accuracy Mean Absolute Relative Difference (MARD), With GST3C Transmitter, Using One Additional Calibration During FST</title>
        <description>Enlite 3 Sensor accuracy using GST3C transmitter used as a recorder compared to YSI or SMBG reference values, with one additional calibration during FST. For subjects 2-6 years of age, SMBG was used as a reference value if YSI cannot be tolerated. MARD = Mean of ((Absolute difference of reference and Sensor glucose values / reference glucose values) * 100). Therefore, the unit of MARD is percentage (%). Note that results from multiple testing days will be pooled together for reporting purpose.</description>
        <time_frame>7 Days</time_frame>
        <population>A total of 41 subjects did not have device data.</population>
        <group_list>
          <group group_id="O1">
            <title>Enlite 3 MARD,GST 3C, One Additional Fingerstick</title>
            <description>Enlite 3 Sensor accuracy using, (1) Guardian Mobile System (2) GST 3C transmitter, with one additional calibration during FST will be evaluated and report. Enlite 3 sensor values will be compared to Yellow Spring Instruments (YSI) plasma glucose values during Frequent Sample Testing in the Enlite 3 phase. For subjects 2-6 years of age, SMBG may be used as a reference value. MARD = Mean of ((Absolute difference of reference and Sensor glucose values / reference glucose values) * 100). Note that results from multiple testing days will be pooled together for reporting purpose.</description>
          </group>
        </group_list>
        <measure>
          <title>Enlite 3 Sensor Accuracy Mean Absolute Relative Difference (MARD), With GST3C Transmitter, Using One Additional Calibration During FST</title>
          <description>Enlite 3 Sensor accuracy using GST3C transmitter used as a recorder compared to YSI or SMBG reference values, with one additional calibration during FST. For subjects 2-6 years of age, SMBG was used as a reference value if YSI cannot be tolerated. MARD = Mean of ((Absolute difference of reference and Sensor glucose values / reference glucose values) * 100). Therefore, the unit of MARD is percentage (%). Note that results from multiple testing days will be pooled together for reporting purpose.</description>
          <population>A total of 41 subjects did not have device data.</population>
          <units>percentage of difference</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.85" spread="10.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>2-18 Year Olds Wearing Enlite Sensors</title>
          <description>2-18 year olds wearing Enlite Sensors</description>
        </group>
        <group group_id="E2">
          <title>2-18 Year Olds Wearing Enlite3 Sensors</title>
          <description>2-18 year olds wearing Enlite3 Sensors</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (15.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pilonidal Abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Influenzavirus B</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic Ketoacidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (15.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>Food poisoning.</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>stomach ache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Insertion site pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>lowgrade fever, maximum 100.8 degrees</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>Food Allergy: Shellfish Positive FPIES (Food PRotein Induced Enterocolitis Syndrome)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Flu symptoms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>Sinus Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>Stomach Virus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>Upper Resiratory Infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>common cold</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>Cold sore</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>hand, foot, mouth disease 0</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Broken right thumb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>Laceration above right knee cap - requiring 9 sutures</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>Left Broken Great Toe</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>Puncture Wound</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>Toe Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>Abrasion on right arm and right leg</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>sprain of left wrist</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Staff Infection left upper arm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>severe hyperglycemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>Hypoglycemic Seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>vasovagal response</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>vasovagal event</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>sore throat</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>skin irritation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>contact dermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>jaw pain due to wisdom teeth removal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Suiying Huang, Statistician</name_or_title>
      <organization>Medtronic Minimed</organization>
      <phone>818-576-3319</phone>
      <email>suiying.huang@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

